ATAI | Investor Presentation Deck | 41 slides · page 14 of 41
The slide contrasts the therapeutic benefit (MADRS) with the lack of side effects (CADSS) compared to S-Ketamine benchmarks.
Conference presentation · before_after · cite_precedent · overcrowded density
Slide locked Sign in to view
Slide schematic 6/6
callout 2/2 chart 2/2 source-note 1/1 title 1/1
Components 6
primary primary line line source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1